ArticleMediterranean journal of hematology and infectious diseases2021
Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL.
Article in Mediterranean journal of hematology and infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- A systematic evaluation of double-expressor lymphoma: prognostic impact, determinants of outcome, and comparative efficacy and safety of novel therapies.Frontiers in oncology · 2026Pooled it
- Optimal peritumoral regions and fusion strategies for prediction of the double-expressor subtype in diffuse large B-cell lymphoma: a multi-region radiomics study.Frontiers in oncology · 2026Article
- Mortality Prediction in Diffuse Large B-Cell Lymphoma Using Supervised Machine Learning Models-A Retrospective Study.Journal of clinical medicine · 2025Article
- Article
- Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects.The oncologist · 2025Review
- Baseline PET/CT metabolic parameters in the double-expressor subtype of diffuse large B-cell lymphoma: development of a clinical-radiologic-pathologic predictive model.Frontiers in oncology · 2025Article
- Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDouble
methodsA retrospective study of 291 patients diagnosed with DLBCL during January 2015
resultsOf the 291 patients, the median age was 63 years, germinal center B cell-like DLBCL
conclusionsHigh incidence of DEL was observed in this study, especially in patients aged 60 years or older and non
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.